1321928-69-1

Basic information

• Product Name: 4-amino-1-((2R,5S)-2-hydroxymethyl-[1,3]oxothiolane-5-yl)-1H-pyrimidin-3-one 2-fluorobenzoic acid salt
• Synonyms: 4-amino-1-((2R,5S)-2-hydroxymethyl-[1,3]oxothiolane-5-yl)-1H-pyrimidin-3-one 2-fluorobenzoic acid salt
• CAS NO: 1321928-69-1
• Molecular Weight: 369.374
• Mol File: 1321928-69-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-amino-1-((2R,5S)-2-hydroxymethyl-[1,3]oxothiolane-5-yl)-1H-pyrimidin-3-one 2-fluorobenzoic acid salt(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-1-((2R,5S)-2-hydroxymethyl-[1,3]oxothiolane-5-yl)-1H-pyrimidin-3-one 2-fluorobenzoic acid salt(1321928-69-1)
• EPA Substance Registry System: 4-amino-1-((2R,5S)-2-hydroxymethyl-[1,3]oxothiolane-5-yl)-1H-pyrimidin-3-one 2-fluorobenzoic acid salt(1321928-69-1)

Safety Data

• Hazardous Substances Data: 1321928-69-1(Hazardous Substances Data)

Upstream product

• 147126-78-1 (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5S)-5-[4-(methylcarboxamido)-2-oxo-1,2-dihydro-1-pyrimidinyl]-1,3-oxathiolane-2-carboxylate 
• 147027-10-9 (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (2R,5S)-5-(4-amino-2-oxo-1,2-dihydro-1-pyrimidinyl)-1,3-oxathiolane-2-carboxylate 
• 445-29-4 o-fluoro-benzoic acid 

Downstream Products

• 134678-17-4 lamivudine 

Relevant articles and documents

NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE

The present invention relates to an improved process for the preparation of cis-nucleoside derivative of formula-1 involving chlorination of the compound of formula-2 followed by reaction with compound of formula-3 in presence of a base to get compound of formula-4, reacting the compound of formula-4 with an alkyl halide (RiX) to get a quaternary ammonium salt then with cytosine derivative of formula-5 to provide the compound of formula-6, optionally de-protecting the compound of formula-6 to the compound of formula-7, reducing compound of formula-7 with metal catalyst in presence of a buffer solution, then adding an organic acid to get the compound of formula-8, and converting the compound of formula-8 to cis-nucleoside derivative of formula-1. The present invention further relates to novel cis-nucleoside derivative of formula-8. The present invention also relates to a pharmaceutical composition comprising cis-nucleoside derivative of formula-1 with excipients.